Efficacy of the Treatment of Infectious Diarrhoea with Non-Absorbable Rifamycin SV Formulated as MMX Modified Release Tablet vs. Rifaximin

Author(s): A.F.D. Di Stefano, D. Binelli, W. Labuschagne, M. Mojapelo, E. van der Walt, S. Patel, L. Moro

Journal Name: Anti-Infective Agents
Formerly Anti-Infective Agents in Medicinal Chemistry

Volume 11 , Issue 2 , 2013

Become EABM
Become Reviewer
Call for Editor


Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.

Keywords: Infectious diarrhoea, MMX, non-absorbable antibiotics, rifamycin SV, rifaximin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 April, 2013
Page: [192 - 203]
Pages: 12
DOI: 10.2174/2211352511311020013
Price: $25

Article Metrics

PDF: 48